Alejandro Martinez Pradeda

Mr. Alejandro Martinez Pradeda


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2024 in Healthcare
Verified
Journal Article
Open access
PDF file
VGVíctor Giménez-Arufe
Víctor Giménez-Arufe
SRSandra Rotea-Salvo
Sandra Rotea-Salvo
APAlejandro Martínez Pradeda
Alejandro Martínez Pradeda
ÁMÁlvaro Mena-De-Cea
Álvaro Mena-De-Cea
LMLuis Margusino-Framiñán
Luis Margusino-Framiñán
PCPURIFICACIÓN CID-SILVA
PURIFICACIÓN CID-SILVA
Early diagnosis of a Human Immunodeficiency Virus (HIV)-infected person represents a cornerstone of HIV prevention, treatment, and care. Numerous publications have developed recommendations where HIV serology is indicated to reduce missed diagnostic opportunities (MDOs). This retrospective study analyses new HIV infection diagnoses and the relationship between late diagnosis (LD)/advanced HIV disease (AHD), baseline characteristics, and MDOs. Sociodemographic data and data related to contact with the health system in the 5 years before diagnosis were collected. Most of the 273 diagnoses were made in primary care (48.5%). Approximately 50.5% and 34.4% had LD and AHD criteria, respectively. Female sex was associated with a higher incidence of LD. Persons infected through the heterosexual route and those at an older age had a higher risk for LD and AHD. People with previous HIV serology presented a lower percentage of LD and AHD. In total, 10% of the health contact instances were classified as MDOs, mostly occurring in primary care. A significant increase in the median of MDOs was observed in patients with LD/AHD. Female sex and hepatitis C virus co-infection were associated with an increase in the number of MDOs. The high percentage of LD and AHD and the significant number of MDOs show that the current screening system should be improved.

11 February 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
TCteresa callelja chucla
teresa callelja chucla
PGPatricia Cordeiro González
Patricia Cordeiro González
APAlejandro Martínez Pradeda
Alejandro Martínez Pradeda
SDSonia Pertega Diaz
Sonia Pertega Diaz
LMLuis Margusino-Framiñán
Luis Margusino-Framiñán
SNSilvia Antolin Novoa
Silvia Antolin Novoa
Objective: To evaluate the differences in overall survival (OS) and progression-free survival (PFS) between men and women with non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) in second-line and later treatments. Methods: A retrospective, single-center observational study was conducted on patients with advanced NSCLC treated with ICIs (nivolumab, pembrolizumab, and atezolizumab) from January 2015 to December 2019 (with follow-up until December 2021). Demographic, clinical, and treatment-related variables were collected. OSand PFSwere analyzed using the Kaplan–Meier method and compared between genders using the log-rank test.A multivariate Cox regression analysis was performed to adjust for confounders. Results: A total of 189 patients were included, and 47 (25%) were women. The most common histology was adenocarcinoma (61%). Women began treatment at a younger age (59.8 vs. 66 years, p < 0.001) and had higher rates of active smoking (46.8% vs. 38%, p = 0.001). The median OS was similar between men (9.5 months, 95% CI: 7.1–11.8) and women (9.2 months, 95% CI: 3.3–15.2; p = 0.382) while PFS was significantly higher in males (3.2 months, 95% CI: 2.5–4.0) than in females (2.1 months; 95% CI = 1.6–2.5) (p = 0.002).Women had higher rates of tumor cachexia (BMI < 20).Worse PFS was observed for women both in the = 25 kg/m2, median OS was higher in women than in men (14.7 months vs. 10.1 months). Women had also a significantly worse PFS than men among those with a cumulative tobacco consumption of = 2 was significantly associated with both worse OS (HR = 3.53; 95% CI = 1.93–6.47) and PFS (HR = 2.19; 95% CI = 1.23–3.89). Women who discontinued due to toxicity (n = 7) had a median OS of 41.4 months (95% CI: 14.7–68.1) after discontinuation, whereas men (n = 15) had a median OS of 8.8 months (95% CI: 6.9–10.8), (p = 0.045). Conclusions: Sex-based differences were observed in the ICI outcomes. Women had worse PFS, particularly with lower BMI and lower tobacco exposure, despite similar OS between sexes. Women discontinued ICIs due to toxicity earlier but showed longer OS after discontinuation. Poor ECOG status was linked to worse outcomes across all the patients.

10 April 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
APAlejandro Martínez Pradeda
Alejandro Martínez Pradeda
LELaida Elberdín
Laida Elberdín
ÁPÁngeles Porta-Sánchez
Ángeles Porta-Sánchez
MOMaría Outeda
María Outeda
MPMª Teresa Diz-Lois Palomares
Mª Teresa Diz-Lois Palomares
MHMarìa Isabel Martín Herranz
Marìa Isabel Martín Herranz
Measuring biological drugs’ trough concentrations and the concentrations of anti-drug antibodies is a valuable practice for treatment optimization. ELISA techniques are the gold standard for biological drug concentration quantification, but new techniques such as chemiluminescence immunoassays present some advantages. The aim of this unicentric prospective observational study is to compare the infliximab, adalimumab, vedolizumab and ustekinumab trough levels and anti-adalimumab and anti-infliximab antibodies concentrations obtained when using a chemiluminescent instrument (i-TRACK®, Theradiag, Croissy-Beaubourg, France) and an ELISA instrument (TRITURUS®, Griffols, Barcelona, Spain). Linear regression, Pearson or Spearman tests, Bland–Altman plots and the Cohen kappa test were applied for every sample. The correlation was excellent for both assays in the measurement of all drug concentrations. In general, values were lower when measured using i-TRACK than when using TRITURUS, especially when the values were high. Both techniques proved valuable in clinical practice for monitoring adalimumab and infliximab drug concentration. However, the results were modest for ustekinumab and vedolizumab, so caution is recommended and further research is needed. The limited number of anti-drug antibody-positive samples precluded a comparison between the techniques.

24 May 2025 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
APAlejandro Martínez Pradeda
Alejandro Martínez Pradeda
PVPablo Feijoo Vilanova
Pablo Feijoo Vilanova
EGElena Fernández Gabriel
Elena Fernández Gabriel
VAVíctor Giménez Arufe
Víctor Giménez Arufe
ALAna María Vale López
Ana María Vale López
VCVíctor Noriega Concepción
Víctor Noriega Concepción
Background: Ibrutinib has transformed chronic lymphocytic leukemia (CLL) treatment, offering significant survival benefits in clinical trials. However, real-world evidence is essential to understand its safety and efficacy in broader patient populations. Objective: To evaluate ibrutinib safety and effectiveness in a real-world cohort of CLL patients focusing on dose reductions, adverse events, and survival outcomes. Methods: This single-center, retrospective, observational study of CLL patients treated with ibrutinib was conducted between January 2015 and June 2023. Data were retrieved from the IANUS electronic medical records including patient demographics, treatment indications, genetic markers, comorbidities, adverse events, and dose changes. Results: This study involved 90 patients with a median age of 71.5 years. Most patients presented with advanced-stage disease (BINET C: 46%, RAI IV: 25%). Cardiovascular comorbidities were common (70%) and 11% had prior bleeding events. Severe adverse events (grade 3-4) occurred in most patients (60%) with infections (33.3%) and neutropenia (14.4%) being the most common. Dose reductions were required in 11.1% of patients mainly due to hematological toxicities and 22% discontinued treatment due to adverse events. However, dose reductions and severe adverse events did not significantly affect overall survival or progression-free survival. The overall response rate was 82.2%, with 42.2% achieving complete remission. Multivariate analysis identified age and comorbidities as significant predictors of severe adverse events but not survival outcomes. Conclusion and Relevance: Ibrutinib remains an effective treatment for lymphocytic leukemia, even in patients with comorbidities and high-risk genetic characteristics. The study supports dose adjustment as a viable strategy for managing toxicities without compromising efficacy. These findings highlight the need for personalized care and proactive management of adverse events in clinical practice, particularly in elderly patients or those with multiple comorbidities. Long-term clinical studies are essential to refine treatment strategies and improve patient outcomes.

26 June 2026 in Exploratory Research in Clinical and Social Pharmacy
Verified
Journal Article
Open access
APAlejandro Martínez Pradeda
Alejandro Martínez Pradeda
EGElena Fernández Gabriel
Elena Fernández Gabriel
SASergio Jimeno Aguado
Sergio Jimeno Aguado
ALAna Sanclaudio Luhia
Ana Sanclaudio Luhia
VCVíctor Noriega Concepción
Víctor Noriega Concepción
LMLuis Margusino-Framiñán
Luis Margusino-Framiñán
Advances in hematologic malignancy treatment have improved survival, but patients often experience treatment-related toxicities. Traditional clinical follow-up often overlooks the patient's subjective experience, highlighting the need for integrated patient-reported outcome measures (PROMs). The primary objective of this study was to describe the design and implementation of the SiMON-PRO-Hematology® system, a comprehensive information tool supporting the pharmacotherapeutic follow-up of patients with hematological malignancies. A secondary objective was to detail the process for PROM collection SiMON-PRO-Hematology was designed by a multidisciplinary team of pharmacists, hematologists, nurses, and software engineers. This group defined the functional requirements of the system, as well as the demographic, clinical, laboratory, and pharmacotherapeutic variables and disease-specific PROMs relevant to hematologic malignancies. The system was structured into three main areas: Clinical care (assistance), management, and research. No primary data were collected; therefore, ethical approval was not required SiMON-PRO-Hematology automates PROM collection via tablet devices completed independently by patients. The platform integrates PROMs with baseline clinical data and laboratory results, generates real-time alerts, and supports structured pharmaceutical interventions. Business intelligence tools enable analysis of patient evolution, treatment adherence, and cohort comparisons. Implementation allows standardized, longitudinal follow-up, enhancing detection of safety and effectiveness signals while streamlining workflows and minimizing documentation duplication. Unlike existing tools, SiMON-PRO-Hematology integrates independently reported PROMs within a broader, adaptable monitoring system tailored to diverse hematologic malignancies This approach ilustrates how a fully integrated digital platform is designed to potentially enhance the quality and efficiency of pharmaceutical care, providing a technical framework to support proactive interventions, longitudinal monitoring, and patient-centered outcomes